Previous 10 | Next 10 |
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Theravance Biopharma, Inc. (TBPH) Q4 2019 Earnings Conference Call February 24, 2020 5:00 PM ET Company Participants Gail Cohen - Vice President, Corporate Communications Rick Winningham - Chief Executive Officer Philip Worboys - Senior Vice President, Research and Translational ...
Theravance Biopharma (NASDAQ: TBPH ): Q4 GAAP EPS of -$1.17 misses by $0.06 . More news on: Theravance Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- YUPELRI® (revefenacin) is realizing strong customer acceptance and market uptake, in partnership with Mylan - Phase 1 of TD-5202 single-ascending dose and multiple-ascending dose studies evaluated the safety and tolerability of TD-5202 in healthy subjects; data showed TD-5202 was...
DUBLIN , Feb. 18, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast Management presentations: SVB Leer...
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Seth Klarman’s Baupost Group Holdings ...
DUBLIN , Feb. 13, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2019 financial an...
Shares of Theravance Biopharma (NASDAQ: TBPH) were sinking 10.7% lower as of 11:04 a.m. EST on Wednesday. This decline came after the drugmaker announced the pricing of a public stock offering after the market closed on Tuesday. Theravance plans to sell 5.5 million new shares at a price of $...
Zosano Pharma (NASDAQ: ZSAN ) -47% after pricing stock offering. More news on: Zosano Pharma Corporation, PolarityTE, Inc., PDS Biotechnology Corporation, Stocks on the move, , Read more ...
Theravance Biopharma (NASDAQ: TBPH ) has priced its public offering of 5.5M ordinary shares at $27.00 per share, for expected gross proceeds of ~$148.5M. More news on: Theravance Biopharma, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 PR Newswire DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update af...
2024-04-24 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...